480 related articles for article (PubMed ID: 30146342)
1. The miR 495-UBE2C-ABCG2/ERCC1 axis reverses cisplatin resistance by downregulating drug resistance genes in cisplatin-resistant non-small cell lung cancer cells.
Guo J; Jin D; Wu Y; Yang L; Du J; Gong K; Chen W; Dai J; Miao S; Xi S
EBioMedicine; 2018 Sep; 35():204-221. PubMed ID: 30146342
[TBL] [Abstract][Full Text] [Related]
2. UBE2C, Directly Targeted by miR-548e-5p, Increases the Cellular Growth and Invasive Abilities of Cancer Cells Interacting with the EMT Marker Protein Zinc Finger E-box Binding Homeobox 1/2 in NSCLC.
Jin D; Guo J; Wu Y; Du J; Wang X; An J; Hu B; Kong L; Di W; Wang W
Theranostics; 2019; 9(7):2036-2055. PubMed ID: 31037155
[No Abstract] [Full Text] [Related]
3. Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential.
Zhao L; Ren Y; Tang H; Wang W; He Q; Sun J; Zhou X; Wang A
Oncotarget; 2015 Dec; 6(42):44538-50. PubMed ID: 26517090
[TBL] [Abstract][Full Text] [Related]
4. miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1.
Deng H; Qianqian G; Ting J; Aimin Y
Biomed Pharmacother; 2018 Oct; 106():1072-1081. PubMed ID: 30119173
[TBL] [Abstract][Full Text] [Related]
5. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of Linc00173 increases BCL2 mRNA stability via the miR-1275/PROCA1/ZFP36L2 axis and induces acquired cisplatin resistance of lung adenocarcinoma.
Tao X; Li Y; Fan S; Wu L; Xin J; Su Y; Xian X; Huang Y; Huang R; Fang W; Liu Z
J Exp Clin Cancer Res; 2023 Jan; 42(1):12. PubMed ID: 36627670
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-1 overexpression increases chemosensitivity of non-small cell lung cancer cells by inhibiting autophagy related 3-mediated autophagy.
Hua L; Zhu G; Wei J
Cell Biol Int; 2018 Sep; 42(9):1240-1249. PubMed ID: 29851226
[TBL] [Abstract][Full Text] [Related]
9. [The reversing and molecular mechanisms of miR-503 on the drug-resistance to cisplatin in A549/DDP cells].
Wu Y; Guo L; Liu J; Liu R; Liu M; Chen J
Zhongguo Fei Ai Za Zhi; 2014 Jan; 17(1):1-7. PubMed ID: 24398307
[TBL] [Abstract][Full Text] [Related]
10. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9.
Liu B; Wang R; Liu H
Biomed Res Int; 2021; 2021():6622342. PubMed ID: 34055989
[TBL] [Abstract][Full Text] [Related]
11. LncRNA CCAT1/miR-130a-3p axis increases cisplatin resistance in non-small-cell lung cancer cell line by targeting SOX4.
Hu B; Zhang H; Wang Z; Zhang F; Wei H; Li L
Cancer Biol Ther; 2017 Dec; 18(12):974-983. PubMed ID: 29020498
[TBL] [Abstract][Full Text] [Related]
12. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
Qi MM; Ge F; Chen XJ; Tang C; Ma J
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
[TBL] [Abstract][Full Text] [Related]
13. MiR-488 inhibits proliferation and cisplatin sensibility in non-small-cell lung cancer (NSCLC) cells by activating the eIF3a-mediated NER signaling pathway.
Fang C; Chen YX; Wu NY; Yin JY; Li XP; Huang HS; Zhang W; Zhou HH; Liu ZQ
Sci Rep; 2017 Jan; 7():40384. PubMed ID: 28074905
[TBL] [Abstract][Full Text] [Related]
14. UBE2C Induces Cisplatin Resistance via ZEB1/2-Dependent Upregulation of ABCG2 and ERCC1 in NSCLC Cells.
Wu Y; Jin D; Wang X; Du J; Di W; An J; Shao C; Guo J
J Oncol; 2019; 2019():8607859. PubMed ID: 30693031
[TBL] [Abstract][Full Text] [Related]
15. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
Xiao XH; He SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line.
Li JH; Luo N; Zhong MZ; Xiao ZQ; Wang JX; Yao XY; Peng Y; Cao J
Tumour Biol; 2016 Feb; 37(2):2387-94. PubMed ID: 26376998
[TBL] [Abstract][Full Text] [Related]
17. Circ_0030998 Restrains Cisplatin Resistance Through Mediating miR-1323/PDCD4 Axis in Non-small Cell Lung Cancer.
Zhu C; Jiang X; Xiao H; Guan J
Biochem Genet; 2022 Dec; 60(6):2434-2454. PubMed ID: 35460386
[TBL] [Abstract][Full Text] [Related]
18. Circular RNAcirc_0076305 Promotes Cisplatin (DDP) Resistance of Non-Small Cell Lung Cancer Cells by Regulating
Wang X; Wang H; Jiang H; Qiao L; Guo C
Cancer Biother Radiopharm; 2023 Jun; 38(5):293-304. PubMed ID: 34339285
[No Abstract] [Full Text] [Related]
19. miR-324-3p reverses cisplatin resistance by inducing GPX4-mediated ferroptosis in lung adenocarcinoma cell line A549.
Deng SH; Wu DM; Li L; Liu T; Zhang T; Li J; Yu Y; He M; Zhao YY; Han R; Xu Y
Biochem Biophys Res Commun; 2021 Apr; 549():54-60. PubMed ID: 33662669
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-106a-5p alleviated the resistance of cisplatin in lung cancer cells by targeting Jumonji domain containing 6.
Ge X; Jiang Y; Hu X; Yu X
Transpl Immunol; 2021 Dec; 69():101478. PubMed ID: 34607003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
